Profile data is unavailable for this security.
About the company
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.
- Revenue in USD (TTM)0.00
- Net income in USD-52.35m
- Incorporated1995
- Employees25.00
- LocationAchieve Life Sciences Inc22722 29TH DR. SE, SUITE 100SEATTLE 98021United StatesUSA
- Phone+1 (425) 686-1500
- Fax+1 (302) 636-5454
- Websitehttps://achievelifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Humacyte Inc | 1.57m | -36.97m | 206.51m | 218.00 | -- | -- | -- | 131.45 | -0.2206 | -0.2206 | 0.011 | -0.0299 | 0.0152 | -- | -- | 7,206.42 | -35.84 | -41.46 | -46.28 | -45.37 | 60.53 | -- | -2,353.22 | -8,438.13 | 0.8965 | -- | 1.10 | -- | -- | -- | -34.24 | -- | -28.00 | -- |
| Neonc Technologies Holdings Inc | 59.99k | -48.88m | 208.31m | 3.00 | -- | -- | -- | 3,472.48 | -2.59 | -2.59 | 0.0032 | -0.6067 | 0.0176 | -- | -- | -- | -1,431.87 | -- | -- | -- | 33.34 | -- | -81,472.06 | -- | -- | -22.45 | -- | -- | 17.80 | -- | 20.26 | -- | -- | -- |
| Prenetics Global Ltd | 92.39m | -52.70m | 215.68m | 285.00 | -- | 0.9907 | -- | 2.33 | -3.60 | -4.02 | 6.58 | 15.43 | 0.443 | 6.38 | 22.48 | -- | -26.36 | -55.58 | -31.23 | -71.68 | 52.97 | 47.68 | -59.49 | -381.63 | 2.76 | -13.87 | 0.01 | -- | 479.76 | 7.23 | -51.06 | -- | 77.92 | -- |
| Heron Therapeutics Inc | 154.90m | -20.20m | 216.82m | 128.00 | -- | 16.30 | -- | 1.40 | -0.1205 | -0.1205 | 0.8733 | 0.0761 | 0.6335 | 0.5668 | 1.84 | 1,210,188.00 | -8.26 | -41.54 | -13.40 | -61.25 | 73.31 | 60.34 | -13.04 | -88.20 | 1.51 | -0.2662 | 0.9075 | -- | 7.36 | 11.81 | -48.71 | -- | -45.86 | -- |
| Angion Biomedica Corp | 0.00 | -45.86m | 218.62m | 32.00 | -- | 56.53 | -- | -- | -3.15 | -3.15 | 0.00 | 0.2211 | 0.00 | -- | -- | 0.00 | -137.56 | -106.87 | -179.35 | -289.86 | -- | -- | -- | -778.01 | -- | -302.49 | 0.7181 | -- | -- | -- | -47.46 | -- | -18.50 | -- |
| Context Therapeutics Inc | 0.00 | -26.44m | 218.67m | 12.00 | -- | 2.99 | -- | -- | -0.2835 | -0.2835 | 0.00 | 0.7964 | 0.00 | -- | -- | 0.00 | -31.94 | -44.73 | -33.64 | -57.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.52 | -- | -- | -- |
| Ovid Therapeutics Inc | 6.61m | -36.33m | 221.31m | 23.00 | -- | 2.71 | -- | 33.48 | -0.5112 | -0.5112 | 0.093 | 0.6282 | 0.0794 | -- | -- | 287,391.30 | -43.64 | -13.89 | -49.07 | -15.44 | -- | -- | -549.62 | -40.79 | -- | -- | 0.00 | -- | 44.50 | -- | 49.50 | -- | -7.98 | -- |
| Arcturus Therapeutics Holdings Inc | 97.60m | -66.71m | 224.74m | 174.00 | -- | 0.9593 | -- | 2.30 | -2.46 | -2.46 | 3.60 | 8.25 | 0.2989 | -- | 5.12 | 560,919.60 | -20.43 | -19.22 | -24.18 | -24.16 | -- | -- | -68.35 | -68.95 | -- | -- | 0.00 | -- | -8.69 | 48.93 | -172.30 | -- | -4.55 | -- |
| Voyager Therapeutics Inc | 31.32m | -126.78m | 226.29m | 172.00 | -- | 1.03 | -- | 7.23 | -2.17 | -2.17 | 0.5358 | 3.96 | 0.0877 | -- | 2.64 | 182,069.80 | -35.50 | -1.01 | -39.95 | -1.27 | -- | -- | -404.85 | -2.34 | -- | -- | 0.00 | -- | -68.00 | -5.18 | -149.12 | -- | -14.53 | -- |
| Surrozen Inc | 3.60m | -86.91m | 230.14m | 40.00 | -- | -- | -- | 63.86 | -19.76 | -19.76 | 0.6008 | -2.74 | 0.0507 | -- | 0.4882 | 90,100.00 | -122.36 | -60.48 | -134.33 | -68.26 | -- | -- | -2,411.38 | -993.19 | -- | -- | -- | -- | -- | -- | -47.68 | -- | -55.92 | -- |
| Achieve Life Sciences Inc | 0.00 | -52.35m | 230.50m | 25.00 | -- | 6.80 | -- | -- | -1.38 | -1.38 | 0.00 | 0.6365 | 0.00 | -- | -- | 0.00 | -104.74 | -95.73 | -125.36 | -142.31 | -- | -- | -- | -- | -- | -- | 0.2271 | -- | -- | -- | -33.58 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -28.87m | 230.74m | 13.00 | -- | 12.15 | -- | -- | -1.31 | -1.31 | 0.00 | 0.7171 | 0.00 | -- | -- | 0.00 | -105.10 | -123.50 | -188.03 | -201.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.95 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 0.00 | -47.66m | 230.92m | 15.00 | -- | 1.96 | -- | -- | -1.15 | -1.15 | 0.00 | 0.9745 | 0.00 | -- | -- | 0.00 | -113.51 | -56.32 | -131.71 | -65.21 | -- | -- | -- | -1,965.97 | -- | -- | 0.00 | -- | -100.00 | -- | -44.62 | -- | -- | -- |
| Alector Inc | 21.05m | -142.93m | 232.87m | 103.00 | -- | 7.60 | -- | 11.07 | -1.39 | -1.39 | 0.2043 | 0.2777 | 0.0553 | -- | -- | 204,320.40 | -37.54 | -18.23 | -50.42 | -22.68 | -- | -- | -679.16 | -100.47 | -- | -- | 0.2402 | -- | -79.07 | -0.0503 | -20.06 | -- | -61.79 | -- |
| OmniAB Inc | 21.09m | -63.67m | 249.04m | 114.00 | -- | 0.8976 | -- | 11.81 | -0.5906 | -0.5906 | 0.1956 | 1.93 | 0.0658 | -- | 6.40 | 185,035.10 | -19.86 | -- | -20.75 | -- | 27.71 | -- | -301.83 | -101.09 | 4.96 | -- | 0.00 | -- | -22.75 | 7.58 | -22.55 | -- | 49.04 | -- |
| Palisade Bio Inc | 0.00 | -11.23m | 251.82m | 8.00 | -- | 4.80 | -- | -- | -2.98 | -2.98 | 0.00 | 0.3522 | 0.00 | -- | -- | 0.00 | -137.67 | -130.84 | -221.20 | -165.85 | -- | -- | -- | -31,830.91 | -- | -1,041.55 | 0.0616 | -- | -100.00 | -- | -17.38 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Achieve Life Sciences Inc's reporting currency: US Dollar USD
30.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Franklin Advisers, Inc.as of 31 Dec 2025 | 4.37m | 8.21% |
| Propel Bio Management LLCas of 31 Dec 2025 | 3.79m | 7.11% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.14m | 4.01% |
| Millennium Management LLCas of 31 Dec 2025 | 1.36m | 2.55% |
| Simplify Asset Management, Inc.as of 31 Dec 2025 | 1.18m | 2.23% |
| Marshall Wace LLPas of 31 Dec 2025 | 1.02m | 1.92% |
| Two Sigma Investments LPas of 31 Dec 2025 | 748.62k | 1.41% |
| Nantahala Capital Management LLCas of 31 Dec 2025 | 648.89k | 1.22% |
| LPL Financial LLCas of 31 Dec 2025 | 633.15k | 1.19% |
| Geode Capital Management LLCas of 31 Dec 2025 | 599.61k | 1.13% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
